STOCK TITAN

Gilead Sciences, Inc. - GILD STOCK NEWS

Welcome to our dedicated news page for Gilead Sciences (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gilead Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gilead Sciences's position in the market.

Rhea-AI Summary
Gilead Sciences receives FDA approval for Vemlidy® 25 mg tablets as a once-daily treatment for chronic hepatitis B virus infection in pediatric patients six years and older, showcasing efficacy and safety in a Phase 2 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Dr. Thomas Odeny and Dr. Joannie Ivory, Gilead-sponsored scholars, are awarded the Winn Career Development Award to address health disparities in cancer care for underrepresented populations. The Winn Awards, supported by Gilead, focus on increasing diversity in clinical trials and mentoring early-stage investigators from diverse backgrounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary
Gilead Sciences, Inc. completes the acquisition of CymaBay Therapeutics, Inc. for $4.3 billion, enhancing its liver disease treatment portfolio with seladelpar for primary biliary cholangitis. The transaction reduces Gilead's 2024 EPS by approximately $3.10 - $3.20 due to acquisition costs and operating expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
acquisition
Rhea-AI Summary
Gilead Sciences collaborates with HIV advocacy groups to increase testing and awareness in Türkiye, providing free tests and treatment. The nation faces a growing HIV epidemic with plans for biannual testing weeks to combat stigma and misinformation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
Rhea-AI Summary
The Center for Disease Analysis Foundation (CDA Foundation) announces the recipients of the CDAF-Relink grant funded by Gilead Sciences (Nasdaq: GILD) to reconnect Hepatitis B and C patients to care. The program received an eight-million-dollar grant from Gilead, distributing 2.1 million dollars to 14 grantees in the first round.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
Rhea-AI Summary
Gilead Sciences, Inc. (GILD) announced the expiration of the waiting period under the HSR Act for its cash tender offer for CymaBay Therapeutics, Inc. The offer conditions are being met, with the tender offer set to expire on March 21, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
Rhea-AI Summary
Gilead Sciences announces positive results from Phase 3 trial of Trodelvy in metastatic triple-negative breast cancer, boosting hopes for improved treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary
Gilead Sciences, Inc. presents new data on Biktarvy for people with HIV and comorbid conditions at the 31st CROI. Studies evaluate efficacy and safety for HIV/HBV and HIV/TB coinfections. Positive results show potential benefits of Biktarvy in treating both conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary
Gilead Sciences and Merck announce positive Phase 2 clinical study results for a potential long-acting oral combination treatment for people with HIV. The investigational combination of islatravir and lenacapavir maintained a high rate of viral suppression at 24 weeks, supporting its development as a once-weekly oral regimen. This novel treatment option aims to address adherence and stigma challenges faced by individuals with HIV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
clinical trial
Rhea-AI Summary
Gilead Sciences and Merck announce positive Phase 2 clinical study results for a potential long-acting oral combination treatment for people with HIV. The investigational combination of islatravir and lenacapavir maintained a high rate of viral suppression at 24 weeks, supporting its development as a once-weekly oral regimen. This novel treatment option aims to address adherence and stigma challenges faced by individuals with HIV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
clinical trial
Gilead Sciences, Inc.

Nasdaq:GILD

GILD Rankings

GILD Stock Data

91.25B
1.24B
0.1%
88.53%
1.55%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Foster City

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.